WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 9, 2006--Interleukin Genetics, Inc. (AMEX: ILI) today reported financial results for the second quarter and six months ended June 30, 2006. The Company generated revenue of $1.3 million in the second quarter of 2006 and a net loss of $923,000, or $(0.04) per basic and diluted common share, for the quarter. Interleukin Genetics’ reported revenues resulted almost entirely from the processing of genetic assessment tests for cardiovascular health and general nutrition.
